We modeled the viral dynamics of 13 untreated patients infected with severe acute respiratory
syndrome‐coronavirus 2 to infer viral growth parameters and predict the effects of antiviral …

In the current COVID-19 pandemic context, proposing and validating effective treatments
represents a major challenge. However, the scarcity of biologically relevant pre-clinical models …

IFN-I and IFN-III immunity in the nasal mucosa is poorly characterized during SARS-CoV-2
infection. We analyze the nasal IFN-I/III signature, namely the expression of ISGF-3–…

Coronavirus disease 2019 (COVID-19) has rapidly become a global pandemic and no antiviral
drug or vaccine is yet available for the treatment of this disease 1 , 2 – 3 . Several clinical …

The diversity of vaccination modalities and infection history are both variables that have an
impact on the immune memory of individuals vaccinated against SARS-CoV-2. To gain more …

Autoantibodies neutralizing type I interferons (IFNs) can underlie critical COVID-19
pneumonia and yellow fever vaccine disease. We report here on 13 patients harboring …

In response to the current pandemic caused by the novel SARS-CoV-2, identifying and
validating effective therapeutic strategies is more than ever necessary. We evaluated the in vitro …

During their nuclear replication stage, influenza viruses hijack the host splicing machinery
to process some of their RNA segments, the M and NS segments. In this review, we provide …

Adenoviruses infect a wide range of vertebrates including humans. Their icosahedral capsids
are composed of three major proteins: the trimeric hexon forms the facets and the penton, …

Influenza A viruses cause annual influenza epidemics and occasional severe pandemics.
Their genome is segmented into eight fragments, which offers evolutionary advantages but …